Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression

Oral Diseases

Volumn 20, Issue 3, 2014, Pages

  Lauxen, I S ^a   Oliveira, M G ^a   Rados, P V ^a   Lingen, M W ^b   Nor J E ^c   Sant'Ana Filho, M ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; Cell cycle; Diagnostic markers; Oral squamous cell carcinoma; Survival

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN P63; SURVIVIN; APOPTOSIS REGULATORY PROTEIN; BIRC5 PROTEIN, HUMAN; CKAP4 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; ANTIBODY LABELING; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CELL CYCLE REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; ORAL BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; VERY ELDERLY; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS;

EID: 84896082838     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12136     Document Type: Article

References (34)

1. Bascones C, Gonzalez-Moles MA, Esparza G et al (2005). Apoptosis and cell cycle arrest in oral lichen planus: hypothesis on their possible influence on its malignant transformation. Arch Oral Biol 50: 873-881.
2. Bidaud P, Chasle J, Sichel F et al (2010). Expression of p53 family members and CD44 in oral squamous cell carcinoma (OSCC) in relation to tumorigenesis. Histol Histopathol 25: 331-339.
3. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A (2009). Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 48: 811-821.
4. Candi E, Rufini A, Terrinoni A et al (2006). Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ 13: 1037-1047.
5. Candi E, Cipollone R, di Val Cervo PR, Gonfloni S, Melino G, Knight R (2008). p63 in epithelial development. Cell Mol Life Sci 65: 3126-3133.
6. Choi H, Tucker SA, Huang Z et al (2003). Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis. Int J Oncol 22: 409-414.
7. De Maria S, Pannone G, Bufo P et al (2009). Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol 135: 107-116.
8. Gomes CC, Drummond SN, Guimarães AL, Andrade CI, Mesquita RA, Gomez RS (2008). P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma. J Oral Pathol Med 37: 151-156.
9. Grizzi F, Di Ieva A, Russo C et al (2006). Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model 17: 3-37.
10. Gurgel CA, Ramos EA, Azevedo RA et al (2008). Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol 39: 311-316.
11. Herbst RS (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59: 21-26.
12. Hibi K, Trink B, Patturajan M et al (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97: 5462-5467.
13. Katz M, Amit I, Citri A et al (2007). A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 9: 961-969.
14. Keski-Säntti H, Atula T, Tikka J, Hollmén J, Mäkitie A, Leivo I (2007). Predictive value of histopathologic parameters in early squamous cell carcinoma of oral tongue. Oral Oncol 43: 1007-1013.
15. Kummoona R, Mohammad Sámi S, Al-Kapptan I, Al-Muala H (2007). Study of antiapoptotic gene of oral carcinoma by using bcl-2 oncogene. J Oral Pathol Med 37: 345-351.
16. Laimer K, Spizzo G, Gastl G et al (2007). High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 43: 193-198.
17. Little N, Jochemsen A (2002). p63. Int J Biochem Cell Biol 34: 6-9.
18. Mallick S, Patil R, Gyanchandani R et al (2009). Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1. J Pathol 217: 398-407.
19. Mirzayans R, Andrais B, Scott A, Murray D (2012). New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: implications for Cancer Therapy. J Biomed Biotechnol 2012: 170325.
20. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M (2010). EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med 39: 571-578.
21. Németh Z, Velich N, Bogdan S, Ujpál M, Szabó G, Suba ZS (2005). The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma 52: 95-102.
22. Patel MP, Masood A, Patel PS, Chanan-Khan AA (2009). Targeting the Bcl-2. Curr Opin Oncol 21: 516-523.
23. Putti TC, To KF, Hsu HC et al (2002). Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 41: 144-151.
24. Qi G, Kudo Y, Ando T et al (2010). Nuclear survivin expression is correlated with malignant behaviours of head and neck cancer together with Aurora-B. Oral Oncol 46: 263-270.
25. Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA (2009). Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle 8: 3702-3706.
26. Slaughter DP, Southwick HW, Smejkal W (1953). "Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 6: 963-968.
27. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H, Tanzawa H (2003). Expression of an inhibitor of apoptosis, survivin in oral carcinogenesis. J Dent Res 82: 607-611.
28. van der Vorst S, Dekairelle AF, Weynand B, Hamoir M, Gala JL (2012). Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma. Head Neck 34: 1542-1550.
29. van der Waal I (2013). Are we able to reduce the mortality and morbidity of oral cancer: some considerations. Med Oral Patol Oral Cir Bucal 18: e33-e37.
30. WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25: 52-58.
31. WAF1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 13: 453-464.
32. Whyte DA, Broton CE, Shillitoe EJ (2002). The unexplained survival of cells in oral cancer: what is the role of p53? J Oral Pathol Med 31: 125-133.
33. Yang A, Kaghad M, Wang Y et al (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
34. Yang A, Kaghad M, Caput D, McKeon F (2002). On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18: 90-95.